4.00

6.54% -0.28

Prelude Therapeutics Inc (PRLD)

Overview News Price History Option Chain Financials Discussions Forecast

Prelude Therapeutics Inc stock is currently priced at $4.00, with a 24-hour trading volume of 40,209. It has seen a -6.54% decreased in the last 24 hours and a -4.31% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.19 pivot point. If it approaches the $3.95 support level, significant changes may occur.

Previous Close:

$4.28

Open:

$4.29

24h Volume:

40,209

Market Cap:

$219.72M

Revenue:

Net Income/Loss:

$-121.83M

P/E Ratio:

-1.8433

EPS:

-2.17

Net Cash Flow:

$-110.58M

1W Performance:

+7.24%

1M Performance:

-4.31%

6M Performance:

+11.11%

1Y Performance:

-36.51%

1D Range:

$3.99

$4.37

52W Range:

$1.66

$6.14

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name

Prelude Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

302-644-5427

Address

200 Powder Mill Road, Wilmington

Employee

Twitter

Next Earnings Date

2024-06-14

Latest SEC Filings

PRLD's Discussions on Twitter

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-21-22	Downgrade	BofA Securities	Neutral → Underperform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-29-22	Initiated	Jefferies	Buy
Mar-15-22	Downgrade	BofA Securities	Buy → Neutral
Feb-28-22	Downgrade	Barclays	Overweight → Equal Weight
Oct-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-27-21	Upgrade	BofA Securities	Neutral → Buy
Apr-26-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Barclays	Overweight
Nov-20-20	Downgrade	BofA Securities	Buy → Neutral
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Goldman	Neutral
Oct-20-20	Initiated	Morgan Stanley	Equal-Weight

View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

Prelude Therapeutics to Showcase at Citizens JMP Life Sciences Conference - MyChesCo

MyChesCo

Prelude Therapeutics Progresses in Cutting-Edge Cancer Treatment Development - MyChesCo

MyChesCo

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Simply Wall St

Simply Wall St

Prelude Therapeutics Inc Stock (PRLD) Financials Data

Prelude Therapeutics Inc (PRLD) Net Income 2024

PRLD net income (TTM) was -$121.83 million for the quarter ending December 31, 2023, a -5.54% decrease year-over-year.

Prelude Therapeutics Inc (PRLD) Cash Flow 2024

PRLD recorded a free cash flow (TTM) of -$110.58 million for the quarter ending December 31, 2023, a -27.47% decrease year-over-year.

Prelude Therapeutics Inc (PRLD) Earnings per Share 2024

PRLD earnings per share (TTM) was -$2.04 for the quarter ending December 31, 2023, a +16.39% growth year-over-year.

Prelude Therapeutics Inc Stock (PRLD) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Lim Bryant David	Chief Legal Officer, Corp Sec.	May 24 '23	Buy	5.39	2,400	12,936	2,400
Vaddi Krishna	CEO	May 24 '23	Buy	5.01	1,000	5,011	1,066,375
Vaddi Krishna	CEO	May 23 '23	Buy	5.63	11,856	66,749	1,065,375
Chardonnet Laurent	Chief Financial Officer	May 23 '23	Buy	5.50	5,000	27,500	42,165
ORBIMED ADVISORS LLC	Director	May 22 '23	Buy	5.75	869,565	4,999,999	10,119,756
Bonita David P	Director	May 22 '23	Buy	5.75	869,565	4,999,999	10,119,756

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.